معرفی
Paolo Bironzo is an Associate Professor in the Department of Oncology at the University of Turin. His research focuses on oncology, particularly non-small cell lung cancer (NSCLC), malignant mesothelioma, and immunotherapy. He leads multiple clinical trials, including the AtezoMeso phase III trial evaluating atezolizumab in mesothelioma patients. His work integrates genomic profiling, precision medicine, and tumor microenvironment analysis. He contributes to academic governance as part of the Department Council and Research Commission.
Research interests emphasize targeted therapies for genetic mutations (e.g., BRCA1/2, EGFR), immune checkpoint inhibitors, and translational oncology. His recent articles explore PARP inhibitors in mesothelioma, combination therapies for CNS metastases, and de-escalation strategies in NSCLC. He collaborates in initiatives like the IMMUcan consortium and EPROPA program to advance genomic-driven treatment. Teaching roles include courses on palliative care, AI in biomedicine, and clinical nursing.
Key studies include the PECATI trial on lenvatinib/pembrolizumab for thymic tumors and investigations into chemoresistance mechanisms in mesothelioma stem cells. His work addresses real-world treatment outcomes and biomarker-driven decision-making in oncology.
